Lymphoma is not a recognized complication of JIA (Juvenile Idiopathic Arthritis) or of Crohn’s disease. In August 2009, the FDA announced a Humira black box cancer warning after investigating the potential association between Humira and Lymphoma and other cancers among children and young adults using TNF blockers.Īpproximately half of the cancers seen in children and young adults taking TNF blockers were lymphomas, including bother Hodgkin’s and non-Hodgkin’s lymphoma, which is a cancer of cells in the immune system. Warnings have been added to the prescribing information about the possible cancer risk. HUMIRA CANCER SIDE EFFECTS: A study published in the issue of the Journal of the American Medical Association (JAMA) indicated that Humira side effects could increase the risk of developing cancer.
It is widely accepted that the number of such problems reported to the FDA likely only represent between 1% and 10% of all actual adverse events. Since that time, a number of similar Humira problems have been reported. In addition, an analysis of FDA adverse event reports during the first two years Humira was on the market identified at least 9 reports of neurological problems with Humira, including two cases of optic neuritis. Of those nerve damage problems, two involved optic neuritis on Humira, which could result in vision loss or sight problems. While other drugs in the same class, such as Enbrel and Remicade, contain warnings about the risks, Abbott has not provided adequate warnings to physicians and consumers, which could have prevented serious injury and permanent nerve damage.ĭuring clinical trials, at least three cases of demyelination with Humira use were reported, compared to no reported cases among those taking a placebo. Lawsuits over Humira have alleged that Abbott downplayed the risk of nerve damage from Humira, including a risk of Central Nervous System (CNS) demyelination and harm to the optic nerve. HUMIRA NERVE DAMAGE AND VISION PROBLEMS Adverse event reports have suggested that Humira may increase the risk of nerve damage, which could cause: OVERVIEW: Humira (adalimumab) is a tumor necrosis factor blocker, also known as TNF blocker, which is approved for treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis, which was previously called juvenile rheumatoid arthritis. >SUBMIT INFORMATION ABOUT A POTENTIAL HUMIRA INJURY<<
0 kommentar(er)
